GRCE · Grace Therapeutics, Inc. · Metrics
Market Cap
$40.60M
Shares
21.04M
Volume · Oct 23
47.23K
Avg daily vol (3M)
162.26K
GRCE metrics
67 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$1.93
Market cap
$40.60M
Price action
20 metricsPrice change (1W)
+2.1%
Price change (30D)
-9.0%
Price change (3M)
-17.2%
Price change (6M)
-16.1%
Price change (YTD)
-44.2%
Price change (1Y)
-38.7%
Trailing year
Price change (5Y)
—
52-week high
$5.13
52-week low
$1.88
Change from 52-week high
-62.4%
Change from 52-week low
+2.7%
Annualized volatility
71.0%
Annualized volatility (3M)
38.7%
Beta
0.9
RSI (14D)
41.5
Price vs SMA 50
-8.0%
Price vs SMA 200
-32.6%
Avg volume (3M)
162,262
Relative volume
0.3
Average dollar volume
$344,200
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
21.04M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.8
reciprocal yield 118.7%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-49.8%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2023-02-14
Profitability
9 metricsGross margin
100.0%
Operating margin
-15.6%
Trailing 12 months
Net margin
-9.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$23.90M
Net income (TTM)
−$20.22M
Trailing 12 months
Diluted EPS (TTM)
$-1.17
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+8.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-41.9%
Return on assets
-40.4%
Debt / equity
0.0
Current ratio
11.5
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$13.76M
Latest balance sheet
Cash & equivalents
$13.76M
Total assets
$50.07M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$10.29M
Capital expenditures (TTM)
—
R&D (TTM)
$2.15M
SG&A (TTM)
—
Stock compensation (TTM)
$601,000
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
33
13F filer change QoQ
-2
Institutional ownership
19.0%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
15.6%
Private-fund adviser ownership
12.9%
Active holders' share change QoQ
-12.1%
Holder tenure
3.2
Price vs estimated holder cost
-33.6%
Ownership (registered funds)
1 metricsIndex-fund ownership
2.2%
Short interest
3 metricsShort interest
8.2%
Latest settlement · 19.0 days to cover
Days to cover
19.0d
Short-squeeze score
70 / 100
Insider activity
2 metricsNet insider buying (90D)
$214,000
Insider-sentiment score
86 / 100
Risk flags
1 metricsGoing concern
—